Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) issued its quarterly earnings results on Thursday, July 27th. The specialty pharmaceutical company reported ($2.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($4.40) by $2.24, Morningstar.com reports. The company had revenue of $34.32 million for the quarter.
Shares of Pernix Therapeutics Holdings (PTX) traded down 4.79% on Tuesday, reaching $2.78. The company had a trading volume of 268,834 shares. Pernix Therapeutics Holdings has a one year low of $0.40 and a one year high of $7.15. The company’s market capitalization is $30.90 million. The company’s 50-day moving average is $3.94 and its 200-day moving average is $3.82.
Separately, ValuEngine downgraded Pernix Therapeutics Holdings from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th.
ILLEGAL ACTIVITY WARNING: “Pernix Therapeutics Holdings, Inc. (PTX) Announces Earnings Results” was published by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/pernix-therapeutics-holdings-inc-ptx-issues-quarterly-earnings-results-updated/1305453.html.
Several hedge funds have recently made changes to their positions in PTX. Bank of New York Mellon Corp increased its stake in shares of Pernix Therapeutics Holdings by 27.8% in the first quarter. Bank of New York Mellon Corp now owns 31,710 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 6,907 shares during the last quarter. California Public Employees Retirement System purchased a new stake in shares of Pernix Therapeutics Holdings during the first quarter valued at approximately $163,000. Finally, Renaissance Technologies LLC increased its stake in shares of Pernix Therapeutics Holdings by 6.9% in the first quarter. Renaissance Technologies LLC now owns 740,650 shares of the specialty pharmaceutical company’s stock worth $2,740,000 after buying an additional 47,700 shares in the last quarter. Hedge funds and other institutional investors own 15.63% of the company’s stock.
Pernix Therapeutics Holdings Company Profile
Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.
Receive News & Ratings for Pernix Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics Holdings Inc. and related companies with our FREE daily email newsletter.